Collectively, these findings suggest that in OSCC patients, low PON2 tumor levels predict absence of relapses, whereas higher PON2 levels correlate with elevated β-catenin expression, at least in the majority of cases, and may predict relapse occurrence even after accompanying irradiation therapy. Here, PON2 is linked to neoplasm.